Otonomy (Otonomy) Tax Provision : $0.00 Mil (TTM As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Otonomy Tax Provision?

Otonomy's tax provision for the three months ended in Sep. 2022 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.

Otonomy Tax Provision Historical Data

The historical data trend for Otonomy's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Otonomy Tax Provision Chart

Otonomy Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Tax Provision

Get a 7-Day Free Trial

Otonomy Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Otonomy Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Otonomy (Otonomy) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Otonomy Inc (OTCPK:OTIC) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

4796 Executive Drive, San Diego, CA, USA, 92121

Website

https://www.otonomy.com

Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.

Executives

Hogan H Michael Iii	director	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Alan Charles Foster	officer: Chief Scientific Officer	4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Savel Robert Michael Ii	officer: Chief Technical Officer	1025 OPAL WAY, VACAVILLE CA 95687
Paul E Cayer	officer: CFO/Ch. Business Offcr & Sec.	C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
David Allen Weber	director, officer: President & CEO	C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Jill Marie Broadfoot	director	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ciara Kennedy	director	C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
James B Breitmeyer	director
Eric J Loumeau	officer: GC & Chief Compliance Officer	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Katherine Mary Bishop	officer: Chief Scientific Officer	C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Carl Lebel	officer: Chief Scientific Officer	23256 MARIPOSA DE ORO, MALIBU CA 90265
Iain Mcgill	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Chau Quang Khuong	director	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022